Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NTRA

Natera Inc

Nov 28 • 02:43PM ET

54.96

Dollar change -0.08
Percentage change -0.15	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.51	Insider Own	8.52%	Shs Outstand	111.25M	Perf Week	0.31%
Market Cap	6.60B	Forward P/E	-	EPS next Y	-2.66	Insider Trans	-0.81%	Shs Float	109.92M	Perf Month	43.65%
Income	-499.34M	PEG	-	EPS next Q	-0.76	Inst Own	92.87%	Short Float / Ratio	6.70% / 5.84	Perf Quarter	-1.66%
Sales	988.72M	P/S	6.68	EPS this Y	30.06%	Inst Trans	1.79%	Short Interest	7.36M	Perf Half Y	16.74%
Book/sh	6.59	P/B	8.33	EPS next Y	31.62%	ROA	-40.67%	Target Price	71.87	Perf Year	46.25%
Cash/sh	7.79	P/C	7.05	EPS next 5Y	-	ROE	-87.12%	52W Range	35.02 - 63.00	Perf YTD	36.82%
Dividend	-	P/FCF	-	EPS past 5Y	-16.55%	ROI	-43.97%	52W High	-12.76%	Beta	1.31
Dividend %	-	Quick Ratio	4.23	Sales past 5Y	32.14%	Gross Margin	42.77%	52W Low	56.94%	ATR	1.99
Employees	3018	Current Ratio	4.37	Sales Q/Q	27.38%	Oper. Margin	-50.92%	RSI (14)	72.30	Volatility	2.63% 4.09%
Optionable	Yes	Debt/Eq	0.56	EPS Q/Q	24.37%	Profit Margin	-50.50%	Rel Volume	0.35	Prev Close	55.04
Shortable	Yes	LT Debt/Eq	0.45	Earnings	Nov 08 AMC	Payout	-	Avg Volume	1.26M	Price	54.96
Recom	1.47	SMA20	15.27%	SMA50	21.43%	SMA200	9.72%	Volume	361,723	Change	-0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150
Jun-15-21	Initiated	Raymond James	Mkt Perform
May-25-21	Initiated	Wells Fargo	Overweight	$110
Jan-28-21	Initiated	Truist	Buy	$143
Oct-08-20	Initiated	BTIG Research	Buy	$90
Sep-28-20	Initiated	Morgan Stanley	Overweight	$80
Sep-17-20	Initiated	SVB Leerink	Outperform	$75
Jun-10-20	Resumed	Piper Sandler	Overweight	$56 → $63
May-07-20	Upgrade	JP Morgan	Neutral → Overweight	$32 → $45
Oct-05-18	Initiated	JP Morgan	Neutral	$26
Jul-05-18	Reiterated	Piper Jaffray	Overweight	$18 → $21

Show Previous Ratings

Nov-23-23 11:03AM	Insider Sell: CEO Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Nov-14-23 08:00AM	Natera Announces Real-World Data Collaboration with Merck (Business Wire) +7.38%
Nov-13-23 11:24AM	Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:02PM	Natera: Q3 Earnings Snapshot (Associated Press Finance) -5.27%
04:05PM	Natera Reports Third Quarter 2023 Financial Results (Business Wire)
09:10AM	Loading…
09:10AM	Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer (Business Wire)
Nov-07-23 08:30AM	Natera to Participate in November Investor Conferences (Business Wire)
Nov-02-23 08:30AM	Nateras Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease (Business Wire)
Oct-25-23 09:02AM	Insider Sell: CFO Michael Brophy Sells 3,940 Shares of Natera Inc (GuruFocus.com)
Oct-22-23 01:00PM	Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signateras Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients (Business Wire)
Oct-20-23 09:00AM	Natera to Report its Third Quarter 2023 Results on November 8 (Business Wire)
Oct-19-23 09:00AM	Natera Recognized on U.S. News & World Reports 2024 Best Companies to Work for in Healthcare Ranking (Business Wire)
Oct-17-23 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (PR Newswire)
Oct-16-23 09:00AM	Natera to Present New Signatera MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study (Business Wire)
Oct-04-23 09:00AM	New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signateras Ability to Risk Stratify and Detect Progression Early (Business Wire)
04:43PM	Loading…
Oct-03-23 04:43PM	Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera (Business Wire)
Oct-02-23 09:00AM	Natera Submits First PMA Module to the FDA for Signatera (Business Wire)
Sep-30-23 05:01AM	Insider Sell: CFO Michael Brophy Sells 2,291 Shares of Natera Inc (GuruFocus.com)
Sep-18-23 09:00AM	Natera Announces Senior Leadership Appointments (Business Wire)
Sep-14-23 07:37PM	Unveiling Natera (NTRA)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com) -5.21%
09:00AM	Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera for Breast Cancer Patients in the Neoadjuvant Setting (Business Wire)
Sep-07-23 12:09AM	Natera Announces Pricing of $250 Million Follow-On Offering (Business Wire)
Sep-06-23 04:24PM	Natera Launches Proposed Follow-On Offering (Business Wire)
Sep-05-23 10:09AM	Natera (NTRA) Reported Solid Quarterly Revenue Despite a Share Price Decline (Insider Monkey)
Sep-04-23 12:17PM	Why Natera Inc's Stock Skyrocketed 27% in a Quarter: A Deep Dive (GuruFocus.com)
Sep-01-23 09:00AM	Natera to Participate in Upcoming Investor Conferences (Business Wire) +6.45%
Aug-18-23 07:39AM	Stanley Druckenmiller 13F Portfolio: Top 15 Stocks (Insider Monkey)
Aug-16-23 09:00AM	Nateras Prospera Lung Transplant Assessment Test Granted Medicare Coverage (Business Wire)
Aug-11-23 01:37PM	Natera Stock Showing Rising Market Leadership, Earns 82 RS Rating (Investor's Business Daily) +5.38%
Aug-05-23 06:27AM	Natera, Inc. (NASDAQ:NTRA) Q2 2023 Earnings Call Transcript (Insider Monkey)
11:15AM	Loading…
Aug-04-23 11:15AM	Why Natera Stock Is Soaring Today (Motley Fool) +17.56%
06:58AM	Q2 2023 Natera Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 05:03PM	Natera: Q2 Earnings Snapshot (AP Finance)
04:05PM	Natera Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-02-23 04:05PM	Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-31-23 01:39PM	Natera Files Patent Infringement Suit Against NeoGenomics (Business Wire)
Jul-28-23 09:00AM	Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera in Colorectal Cancer (Business Wire)
Jul-27-23 08:00AM	Natera to Report its Second Quarter 2023 Results on August 3rd (Business Wire)
Jul-22-23 03:25PM	20 Countries With Highest Rate Of Down Syndrome (Insider Monkey)
Jul-17-23 04:47PM	Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages (Business Wire)
Jul-14-23 09:34AM	The five-year returns have been stellar for Natera (NASDAQ:NTRA) shareholders despite underlying losses increasing (Simply Wall St.)
Jun-06-23 08:30AM	Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-04-23 07:08PM	Natera Announces Data from the ProActive Study that Supports Prospera Kidney as an Early Indicator of Transplant Rejection (Business Wire)
May-30-23 08:30AM	New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types (Business Wire)
May-16-23 11:03AM	Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation? (Simply Wall St.)
May-15-23 04:27PM	Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case (Reuters)
04:24PM	Natera wins $19 mln US verdict from ArcherDX in cancer-detection patent case (Reuters)
01:48PM	Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits (Business Wire)
May-09-23 05:07PM	Natera: Q1 Earnings Snapshot (AP Finance)
04:05PM	Natera Reports First Quarter 2023 Financial Results (Business Wire)
04:55AM	Heres Why Natera (NTRA) Outperformed in Q1 (Insider Monkey)
May-08-23 08:00AM	Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera for Breast Cancer Patients in the Neoadjuvant Setting (Business Wire)
May-02-23 08:00AM	Natera Announces First Quarter 2023 Earnings Conference Call (Business Wire)
Apr-19-23 09:39AM	Revenues Working Against Natera, Inc.'s (NASDAQ:NTRA) Share Price (Simply Wall St.) +5.82%
Apr-14-23 08:00AM	Natera Announces New Signatera MRD Data at 2023 AACR Annual Meeting (Business Wire)
Mar-22-23 08:00AM	New Publication Demonstrates Utility of Nateras Signatera Test in Melanoma (Business Wire)
Mar-02-23 07:00AM	Natera Announces Commercial Payor Coverage for Signatera (Business Wire)
Feb-28-23 08:05PM	Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Natera Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 08:34AM	Is a Surprise Coming for Natera (NTRA) This Earnings Season? (Zacks)
Feb-24-23 08:00AM	Natera to Participate in Upcoming Investor Conferences (Business Wire)
Feb-23-23 08:05AM	Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors (Business Wire)
Feb-21-23 08:00AM	Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call (Business Wire) -5.13%
Feb-16-23 04:06PM	Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today (Investor's Business Daily) +16.93%
08:00AM	Medicare Extends Coverage of Nateras Signatera MRD Test to Breast Cancer (Business Wire)
Feb-04-23 08:14AM	Natera's (NASDAQ:NTRA) investors will be pleased with their fantastic 394% return over the last five years (Simply Wall St.)
Feb-02-23 08:01AM	New Paper Highlights Clinical Utility of Nateras Renasight Test in the Management of Kidney Disease (Business Wire) +5.87%
Jan-24-23 07:42PM	Raymond James Sees Multiple Expansion to Drive Stock Market Returns Here Are 2 Stocks to Play That Bullish Sentiment (TipRanks)
Jan-19-23 08:02AM	New Signatera MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023 (Business Wire)
Jan-18-23 01:11PM	Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock (Benzinga)
Jan-17-23 08:01AM	Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signateras Ability to Predict Chemotherapy Benefit in Colorectal Cancer (Business Wire)
Jan-12-23 09:55AM	Wall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a Bet (Zacks)
Jan-03-23 04:05PM	Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
09:39AM	A Natera, Inc. (NASDAQ:NTRA) insider increased their holdings by 13% last year (Simply Wall St.)
Dec-21-22 07:23PM	Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients (Business Wire)
Dec-09-22 08:33AM	Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers (PR Newswire)
Dec-07-22 09:13AM	After losing 58% in the past year, Natera, Inc. (NASDAQ:NTRA) institutional owners must be relieved by the recent gain (Simply Wall St.)
08:33AM	Natera to Present New Signatera and Empower Data at the 2022 Annual San Antonio Breast Cancer Symposium (PR Newswire)
Dec-06-22 05:31AM	Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama NIPT (PR Newswire)
Dec-05-22 03:49PM	13 Best Genomics Stocks To Buy Now (Insider Monkey)
Nov-23-22 08:33AM	Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference (PR Newswire) +5.11%
Nov-22-22 06:14PM	Biotech companies Natera and Synthego are laying off a total of 163 employees (American City Business Journals)
Nov-21-22 08:33AM	New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients (PR Newswire)
Nov-15-22 11:01PM	Natera Announces Pricing of Follow-On Offering (PR Newswire)
04:30PM	Natera Launches Proposed Follow-On Offering (PR Newswire)
Nov-10-22 05:56AM	Natera Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-08-22 05:55PM	Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Natera Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-04-22 12:51AM	Natera (NTRA) Shares Outperformed in the Third Quarter on Positive Business Updates (Insider Monkey)
Nov-02-22 08:33AM	Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs (PR Newswire)
Nov-01-22 11:00AM	Natera to Participate in Credit Suisse 31st Annual Healthcare Conference (PR Newswire)
08:30AM	Natera to Report its Third Quarter 2022 Results on November 8th (PR Newswire)
Oct-06-22 08:33AM	New Publication Validates Performance of Natera's Signatera MRD Test in Ovarian Cancer (PR Newswire)
Oct-04-22 08:33AM	Trifecta Study Demonstrates Prospera Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection (PR Newswire) +8.71%
Sep-29-22 08:33AM	Natera Announces 2025 ESG Goals with Publication of 2021 Report (PR Newswire)
Sep-12-22 09:27AM	Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings (PR Newswire)
Sep-06-22 01:32PM	Natera to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-22 08:35AM	Natera Earns Great Place to Work Certification for Second Consecutive Year (PR Newswire)
Aug-11-22 07:32AM	Natera Announces Enrollment Completion for RenaCARE Study (PR Newswire)
Aug-10-22 04:15PM	Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT (PR Newswire) +8.80%

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marcus Gail Boxer	Director	Nov 21	Sale	54.31	1,000	54,314	20,646	Nov 22 08:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 20	Sale	55.00	2,566	141,130	217,554	Nov 22 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 02	Sale	40.23	5,000	201,150	479,743	Nov 03 09:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 02	Sale	40.35	1,000	40,351	22,155	Nov 03 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 23	Sale	40.40	3,940	159,195	64,810	Oct 24 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 23	Sale	40.39	2,595	104,813	220,120	Oct 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 23	Sale	40.04	1,000	40,037	22,655	Oct 24 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 23	Sale	40.39	803	32,433	179,807	Oct 24 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 23	Sale	40.19	335	13,464	484,743	Oct 24 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Sep 29	Sale	45.98	1,372	63,080	64,833	Sep 29 09:45 PM
Sheena Jonathan	CO-FOUNDER	Sep 28	Sale	46.06	5,448	250,909	484,745	Sep 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 28	Sale	45.82	2,617	119,901	217,554	Sep 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Sep 28	Sale	45.82	919	42,105	66,205	Sep 29 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Sep 28	Sale	45.82	732	33,537	179,110	Sep 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Sep 06	Sale	59.07	5,000	295,365	489,746	Sep 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Sep 06	Sale	59.23	1,000	59,227	23,155	Sep 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Sep 01	Sale	60.01	10,000	600,062	494,746	Sep 01 09:30 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 11	Sale	55.00	2,578	141,790	214,988	Aug 14 09:05 PM
Sheena Jonathan	CO-FOUNDER	Aug 02	Sale	44.22	5,000	221,116	504,746	Aug 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 02	Sale	44.15	1,000	44,149	23,655	Aug 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 25	Sale	46.58	2,347	109,323	64,833	Jul 27 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 24	Sale	47.83	2,578	123,296	217,566	Jul 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 24	Sale	47.83	1,570	75,087	67,180	Jul 24 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jul 24	Sale	47.83	800	38,261	178,478	Jul 24 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jul 24	Sale	47.82	100	4,782	509,746	Jul 24 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jul 21	Sale	47.56	1,000	47,560	24,155	Jul 24 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jul 21	Sale	47.56	233	11,081	509,846	Jul 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jun 29	Sale	51.11	1,377	70,378	64,833	Jun 29 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jun 28	Sale	50.83	5,447	276,868	509,746	Jun 29 08:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jun 28	Sale	50.88	2,605	132,545	214,983	Jun 29 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jun 28	Sale	50.88	915	46,556	66,210	Jun 29 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jun 28	Sale	50.88	728	37,041	177,778	Jun 29 09:05 PM
Chapman Rowan E	Director	Jun 13	Sale	50.58	1,767	89,366	8,621	Jun 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 07	Sale	49.13	5,000	245,627	514,746	Jun 09 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jun 07	Sale	49.09	1,000	49,095	24,655	Jun 09 09:05 PM
Sheena Jonathan	CO-FOUNDER	May 10	Sale	54.06	5,000	270,319	519,746	May 12 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 25	Sale	50.99	2,364	120,550	64,833	Jun 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 24	Sale	54.98	949	52,176	67,197	Apr 24 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 24	Sale	54.98	885	48,657	212,405	Apr 24 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 24	Sale	54.98	342	18,803	177,143	Apr 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 24	Sale	54.98	43	2,364	524,746	Apr 24 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 21	Sale	54.27	1,689	91,662	211,516	Apr 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 21	Sale	54.27	603	32,725	65,751	Apr 24 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 21	Sale	54.27	454	24,639	176,841	Apr 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 21	Sale	54.23	290	15,727	524,646	Apr 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 03	Sale	54.02	5,000	270,081	524,746	Apr 05 08:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 29	Sale	55.00	2,571	141,405	209,819	Mar 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 29	Sale	55.00	1,375	75,625	64,833	Mar 29 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 28	Sale	55.13	2,612	144,002	212,390	Mar 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 28	Sale	55.13	917	50,555	66,208	Mar 29 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 28	Sale	55.13	731	40,300	176,439	Mar 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Mar 28	Sale	55.13	134	7,388	529,746	Mar 29 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 24	Sale	55.09	1,656	91,229	209,819	Mar 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 24	Sale	55.20	651	35,938	64,833	Mar 24 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 23	Sale	56.08	1,651	92,588	211,475	Mar 24 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 23	Sale	56.08	474	26,582	175,806	Mar 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 23	Sale	56.08	427	23,946	65,484	Mar 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 23	Sale	56.08	135	7,571	529,433	Mar 24 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 23	Sale	56.08	120	6,730	640,084	Mar 24 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 22	Sale	56.32	4,736	266,739	209,819	Mar 24 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 22	Sale	56.32	2,864	161,305	175,387	Mar 24 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 22	Sale	56.32	2,484	139,903	639,803	Mar 24 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 22	Sale	56.32	1,373	77,329	64,833	Mar 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 22	Sale	56.32	1,259	70,909	529,113	Mar 24 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 02	Sale	55.00	40,835	2,245,925	205,128	Mar 03 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 02	Sale	55.96	9,312	521,059	175,387	Mar 03 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 28	Sale	48.94	13,474	659,403	245,963	Mar 01 08:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 28	Sale	48.94	5,498	269,066	184,699	Mar 01 08:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 28	Sale	48.94	5,218	255,363	62,764	Mar 01 08:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 01	Sale	43.68	19,326	844,152	49,664	Feb 01 09:50 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 31	Sale	42.33	35,000	1,481,560	68,990	Feb 01 09:50 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 30	Sale	42.08	48,697	2,049,325	103,990	Feb 01 09:50 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 23	Sale	41.56	5,370	223,176	103,779	Jan 24 08:05 PM
Schueren Robert Alan	CHIEF OPERATING OFFICER	Jan 23	Sale	41.56	4,256	176,878	4,226	Jan 24 08:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 23	Sale	41.56	2,387	99,203	148,853	Jan 24 08:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 23	Sale	41.56	2,273	94,465	103,023	Jan 24 08:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 23	Sale	41.56	51	2,120	520,616	Jan 24 08:05 PM
Schueren Robert Alan	CHIEF OPERATING OFFICER	Jan 10	Option Exercise	13.01	3,938	51,233	11,824	Jan 10 09:05 PM
Schueren Robert Alan	CHIEF OPERATING OFFICER	Jan 09	Sale	37.62	2,244	84,419	7,886	Jan 10 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 03	Sale	39.55	8,212	324,806	93,831	Jan 04 09:05 PM
Schueren Robert Alan	CHIEF OPERATING OFFICER	Jan 03	Sale	39.55	4,856	192,068	6,145	Jan 04 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 03	Sale	39.55	3,644	144,130	96,814	Jan 04 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jan 03	Sale	39.55	2,706	107,030	639,803	Jan 04 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 03	Sale	39.55	1,236	48,888	570,074	Jan 04 09:05 PM
Schueren Robert Alan	CHIEF OPERATING OFFICER	Dec 29	Sale	40.37	5,897	238,075	103,417	Dec 29 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 28	Sale	39.84	2,605	103,790	85,210	Dec 29 09:05 PM
Schueren Robert Alan	CHIEF OPERATING OFFICER	Dec 28	Sale	39.84	1,382	55,062	1,367	Dec 29 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Dec 28	Sale	39.84	915	36,456	91,350	Dec 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 28	Sale	39.84	728	29,005	147,172	Dec 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 28	Sale	39.84	134	5,339	567,169	Dec 29 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 23	Sale	42.30	1,660	70,219	82,632	Dec 27 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 23	Sale	42.30	476	20,135	146,537	Dec 27 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Dec 23	Sale	42.30	429	18,147	89,974	Dec 27 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 23	Sale	42.30	136	5,753	566,856	Dec 27 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 07	Option Exercise	9.70	10,304	99,987	83,630	Dec 09 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 07	Sale	38.31	2,645	101,330	80,985	Dec 09 09:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your FINVIZ experience